Low-dose interleukin-2 (IL-2) was found to be safe and well tolerated in a phase 1 and 2a trial of 12 patients with systemic lupus erythematosus (SLE). The treatment may be beneficial in reducing disease activity, researchers report in Sept. 1 issue of The Lancet Rheumatology.
A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
Anifrolumab, a potential new for lupus, just successfully completed a phase three clinical trial in which patients demonstrated reduced disease activity by significant margins, according to a statement issued by the drug’s maker AstraZeneca.
The Rheumatology Nurses Society met this month for their annual meeting. In this Q&A, we revisit a talk by Monica Richey, MSN, a rheumatology nurse practitioner with Northwell Health in New York who discusses treatment challenges in lupus.
Pregnant women with systemic lupus erythematosus often discontinue their lupus medications during pregnancy despite recommendations to continue them.
Plasma microbial translocation may play a role in the development of autoantibodies in systemic lupus erythematosus, researchers find. The discovery may lead to new treatments in lupus.
A 20-year analysis of hospitalizations due to compliations from systemic lupus erythematosus, shows new patterns in hospitalization rates, disease complications and mortality. In this slideshow, we highlight the findings.
Over the past 20 years, while the demographics of systemic lupus erythematosus (SLE) hospitalizations have not noticeably changed, the comorbidities that lead to hospitalizations and poor outcomes in SLE have changed.
Steriod-related damage builds over time for patients with childhood-onset lupus leading to cataracts, avascular necrosis, diabetes and osteoporotic fractures. Learn more in this slideshow.
New results for baricitinib and ustekinumab use in patients with systemic lupus erythematosus (SLE) were presented in April at the International Congress on Systemic Lupus Erythematosus (LUPUS 2019), which was held in San Francisco. Here, we summarize those results, plus much more from the meeting.